Silo Pharma sets public offering at $0.60 per share and warrant

SARASOTA, FL - Silo Pharma, Inc. (NASDAQ:SILO), a developmental stage biopharmaceutical company with a current market capitalization of $3.75 million, has priced a public offering of securities that is expected to close on May 16, 2025. The offering includes 3,333,338 shares of common stock, or pre-funded warrants as an alternative, along with series A-1 and A-2 warrants to purchase additional shares. According to InvestingPro analysis, the company’s stock is currently trading below its Fair Value.

Each unit, consisting of a share or pre-funded warrant and associated series A-1 and A-2 warrants, is priced at $0.60. The series A-1 warrants, exercisable immediately at $0.60 per share, will expire five years from the issuance date, while the series A-2 warrants, also exercisable immediately at the same price, will expire eighteen months after issuance.

H.C. Wainwright & Co. is serving as the exclusive placement agent for the offering. Silo Pharma anticipates the gross proceeds from the offering to be approximately $2 million, before accounting for placement agent fees and other offering expenses. The net proceeds are intended for general working capital purposes.

The offering is made under a registration statement filed with the Securities and Exchange Commission (SEC), declared effective on the date of the announcement. Prospective investors can obtain the final prospectus, once available, from the SEC’s website or directly from H.C. Wainwright & Co.

Silo Pharma’s portfolio includes therapeutic programs aimed at conditions such as PTSD, chronic pain, and central nervous system diseases, with research partnerships with leading universities and laboratories. The offering’s completion is subject to customary closing conditions. The company boasts impressive gross profit margins of 91.9%, though InvestingPro analysis indicates challenging near-term profitability prospects. Subscribers can access 8 additional ProTips and comprehensive financial metrics for deeper insight into the company’s potential.

This press release does not constitute an offer to sell the securities described and will only be conducted in jurisdictions where it is lawful. The information contained in this announcement is based on a press release statement.

In other recent news, Silo Pharma, Inc. has made several significant advancements in its biopharmaceutical endeavors. The company announced a partnership with Veloxity Labs to conduct bioanalysis for its PTSD treatment candidate, SPC-15, as part of preparations for an IND application to the FDA. Additionally, Silo Pharma has entered into an agreement with Frontage Laboratories for a 7-day safety and toxicology study on SPC-15, fulfilling an FDA request and paving the way for an IND submission anticipated in 2025. In related developments, Silo Pharma reported positive preclinical results for SP-26, its extended-release ketamine implant for fibromyalgia, which met all endpoints in a study conducted on minipigs.

Moreover, Silo Pharma has filed a patent application for SPC-14, a drug aimed at treating Alzheimer’s disease, with the U.S. Patent and Trademark Office. This patent covers the drug’s unique approach to targeting specific receptors associated with the disease’s cognitive and neuropsychiatric symptoms. The company holds an exclusive global license from Columbia University for the development and commercialization of SPC-15, which is designed to treat stress-induced psychiatric disorders. Silo Pharma’s advancements reflect its commitment to developing novel therapeutics for psychiatric disorders, chronic pain, and central nervous system diseases. These recent developments highlight Silo Pharma’s strategic efforts to expand its portfolio and secure intellectual property rights for its innovative drug platforms.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.